Isofol Medical (Sweden) Performance
| ISOFOL Stock | SEK 2.99 0.11 3.82% |
On a scale of 0 to 100, Isofol Medical holds a performance score of 3. The company retains a Market Volatility (i.e., Beta) of -0.61, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Isofol Medical are expected to decrease at a much lower rate. During the bear market, Isofol Medical is likely to outperform the market. Please check Isofol Medical's expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Isofol Medical's current trending patterns will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Isofol Medical AB are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Isofol Medical sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 116.4 M |
Isofol |
Isofol Medical Relative Risk vs. Return Landscape
If you would invest 278.00 in Isofol Medical AB on September 2, 2024 and sell it today you would earn a total of 21.00 from holding Isofol Medical AB or generate 7.55% return on investment over 90 days. Isofol Medical AB is generating 0.2804% of daily returns and assumes 6.0018% volatility on return distribution over the 90 days horizon. Simply put, 53% of stocks are less volatile than Isofol, and 95% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Isofol Medical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Isofol Medical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Isofol Medical AB, and traders can use it to determine the average amount a Isofol Medical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0467
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ISOFOL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.0 actual daily | 53 53% of assets are less volatile |
Expected Return
| 0.28 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Isofol Medical is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Isofol Medical by adding it to a well-diversified portfolio.
Isofol Medical Fundamentals Growth
Isofol Stock prices reflect investors' perceptions of the future prospects and financial health of Isofol Medical, and Isofol Medical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Isofol Stock performance.
| Return On Equity | -0.69 | |||
| Return On Asset | -0.36 | |||
| Operating Margin | (13.09) % | |||
| Current Valuation | (42.41 M) | |||
| Shares Outstanding | 161.52 M | |||
| Price To Book | 0.65 X | |||
| Price To Sales | 7.45 X | |||
| Revenue | 22.41 M | |||
| EBITDA | (198.49 M) | |||
| Cash And Equivalents | 379.45 M | |||
| Cash Per Share | 0.93 X | |||
| Total Debt | 110 K | |||
| Debt To Equity | 0.05 % | |||
| Book Value Per Share | 1.14 X | |||
| Cash Flow From Operations | (188.43 M) | |||
| Earnings Per Share | (1.42) X | |||
| Total Asset | 401.36 M | |||
About Isofol Medical Performance
By analyzing Isofol Medical's fundamental ratios, stakeholders can gain valuable insights into Isofol Medical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Isofol Medical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Isofol Medical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Isofol Medical AB , a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden. Isofol Medical operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 12 people.Things to note about Isofol Medical AB performance evaluation
Checking the ongoing alerts about Isofol Medical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Isofol Medical AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Isofol Medical AB had very high historical volatility over the last 90 days | |
| Isofol Medical AB has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 22.41 M. Net Loss for the year was (200.25 M) with loss before overhead, payroll, taxes, and interest of (174.31 M). | |
| Isofol Medical AB has accumulated about 379.45 M in cash with (188.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.93. | |
| Roughly 26.0% of the company shares are held by company insiders |
- Analyzing Isofol Medical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Isofol Medical's stock is overvalued or undervalued compared to its peers.
- Examining Isofol Medical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Isofol Medical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Isofol Medical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Isofol Medical's stock. These opinions can provide insight into Isofol Medical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Isofol Stock analysis
When running Isofol Medical's price analysis, check to measure Isofol Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Isofol Medical is operating at the current time. Most of Isofol Medical's value examination focuses on studying past and present price action to predict the probability of Isofol Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Isofol Medical's price. Additionally, you may evaluate how the addition of Isofol Medical to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |